Key statistics
As of last trade Harmony Biosciences Holdings Inc (HRMY:NMQ) traded at 37.20, -8.98% below its 52-week high of 40.87, set on Dec 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 36.86 |
|---|---|
| High | 37.48 |
| Low | 36.55 |
| Bid | 37.09 |
| Offer | 37.22 |
| Previous close | 36.01 |
| Average volume | 538.81k |
|---|---|
| Shares outstanding | 57.60m |
| Free float | 50.00m |
| P/E (TTM) | 11.34 |
| Market cap | 2.07bn USD |
| EPS (TTM) | 3.18 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 18:45 GMT.
More ▼
- Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
- Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
- Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
- Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
- Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
- Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
More ▼
